Exciting updates in the field of breast cancer were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting,…
Browsing: Acute Lymphoblastic Leukemia
CAR T-cell monotherapies have produced promising results; however, the duration of remission needs to be optimized. Here, Jeremy Abramson, MD,…
With the recent influx of targeted, highly effective novel agents to the field of acute lymphoblastic leukemia (ALL), there is…
CAR T-cells are gaining traction as a therapy for a variety of hematological malignancies. Here, Oliver Ottmann, MD, FRCPath, of…
Mark Levis, MD, PhD, weighs in on the evolving treatment considerations for FLT3 mutated acute myeloid leukemia (AML) patients who…
Acute lymphoblastic leukemia (ALL) is currently treated with a regimen of drugs that, while effective to an extent, could be…
Dr Laurie Sehn, of the BC Cancer Agency, Vancouver, BC, Canada presents: ‘Answering the unmet need in one of the…
John Leighton, MD, shares the outcomes of the Checkmate 142 study examining ipilimumab and nivolumab in metastatic colorectal cancer (mCRC)…
Atrayee Basu Mallick, MD, shares how how nivolumab is being incorporated into metastatic colorectal cancer (mCRC) treatment algorithms at Annual…
Tomasz M. Beer, MD, explains how immunotherapy is being integrated into CRPC treatment algorithms at Annual Meeting 2018.
Roy S. Herbst, MD, PhD, talks about drug sequencing as a result of Keynote 189 and 42 results at Annual…
Jeanny B. Aragon-Ching, MD, FACP, discusses how checkpoint inhibitors figure into the treatment algorithms for unresectable 1st line renal cell…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, David Marks, MBBS, PhD,…
Measurable residual disease (MRD) is arguably the most useful single prognostic tool we have within the field of acute lymphoblastic…
There are promising results from a variety of studies implicating CAR T-cells in relapsed/refractory acute lymphoblastic leukemia (ALL) treatment. Here,…
Inotuzumab ozogamicin has shown extremely promising results in clinical trials for treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). There are,…
We should move away from using risk factors as individual binary variables within acute lymphoblastic leukemia (ALL) research, suggests Anthony…
The Phase III INO-VATE trial (NCT01564784) showed improved rates of complete remission and overall survival in relapsed/refractory acute lymphoblastic leukemia…
Anthony Moorman, PhD, of Newcastle University, Newcastle, UK, discusses the current UKALL14 trial (NCT01085617) for adults aged 25-65 with acute…
Acute lymphoblastic leukemia (ALL) treatment regimens are long and debilitating, which is especially hard on young adults who are already…
With the remarkable success of the US Bone Marrow Transplant Clinical Trials Network (BMT CNT), founded by Mary Horowitz, in…
Measurable residual disease (MRD) is a significant prognostic factor in acute lymphoblastic leukemia (ALL), and as such it is important…
The prognosis for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) patients is poor, with low overall survival rates; however, novel therapies…
The UK is in a leading position internationally for use of minimal residual disease (MRD) measurements in acute myeloid leukemia…
Richard Dillon, MBBS, from King’s College London, UK, discusses the current landscape for minimal residual disease (MRD) in acute myeloid…
Although there have been significant advancements in the treatment of acute lymphoblastic leukemia (ALL) in the last few decade, many…
Microsatellite instability (MSI) in tumors is a known predictor of response to certain therapies in gynecological cancer. In this video,…
The field of cardio-oncology is growing on both a national and international scale. In this interview, Alex Lyon, MA, BM…
Due to the success of current treatments, patients are living longer and surviving cancer. However, certain treatments can cause cardiac…
Application of 2% Sequester Cut to Medicare Part B Drug Reimbursement is Unconstitutional and Illegal; Costing Seniors and Taxpayers Billions…
Noelle Frey, MD, from the University of Pennsylvania, Philadelphia, PA, highlights the importance of minimal residual disease (MRD) assessment in…
Unlike childhood acute lymphoblastic leukemia (ALL), there are currently no approved CAR T-cell products for the treatment of adult ALL;…
CAR T-cell therapy has proven effective in delivering high response rates in relapsed acute lymphoblastic leukemia (ALL) patients, but what…
Patients suffering from acute myeloid leukemia (AML) who have achieved complete remission are still at risk of relapse. Assessing blood…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Charles Mullighan,…
Minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) is now considered to be an equal, or greater, marker…
Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Childrens Research Hospital, Memphis, TN, discusses the novel and interesting approaches…
Finding the right treatment for a specific subset of acute lymphoblastic leukemia (ALL) requires a correct diagnosis, but there are…
Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Childrens Research Hospital, Memphis, TN, provides an overview of his talk…
Community Oncology Alliance Statement on President’s Blueprint to Lower Drug Prices Putting Cancer Patients First and Lowering Drug is Critically…
Community Oncology Alliance Names Dr. Frederick M. Schnell to Newly Created Medical Director Position Experienced Community Oncologist Will Provide Valuable…
Community Oncology Alliance Statement on White House Budget Proposal Drug Price Recommendations Administration’s Budget has Numerous Smart, Overdue Policy Solutions;…
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell dyscrasia, and can present de novo or following the…
The incorporation of novel biological agents has become the cornerstone of treatment in multiple myeloma (MM). In this video, Torben…
Systemic amyloid light-chain (AL) amyloidosis, a disease with improving outcomes using novel therapies, is increasingly recognized in the elderly, but…
New insights into the biology of multiple myeloma (MM) are continually emerging. In this interview, Martin Kaiser, MD, of the…
A large contributing factor to outcome in amyloidosis is the stage of diagnosis. Here, Giampaolo Merlini, MD, from the University…
This is an exciting time for the treatment of amyloid light-chain (AL) amyloidosis, with a number of novel therapies on…
New insights into amyloid light-chain (AL) amyloidosis have emerged in recent years. Here, Giampaolo Merlini, MD, from the University of…